Mersana Therapeutics (MRSN) Tops Q4 EPS by 4c

Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.11), $0.04 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $16.36 million versus the consensus estimate of $7.38 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Iran deal reopens Strait of Hormuz - Reuters